OBJECTIVES: To evaluate PTX3 feasibility to provide a prognostic tool in PMR clinical practice. METHODS: Circulating PTX3 levels were measured in 93 PMR patients at disease onset and during corticosteroid therapy and in 46 normal controls (NC) by ELISA. RESULTS: No difference in PTX3 concentrations was observed between NC and PMR either at disease onset and during follow-up or between groups of patients defined according to the presence of recurrence/relapse. CONCLUSIONS: PTX3 serum levels do not increase significantly in active PMR. Further studies on patients with giant-cell arteritis could evaluate whether large vessel involvement may be associated to increased PTX3 levels.
OBJECTIVES: To evaluate PTX3 feasibility to provide a prognostic tool in PMR clinical practice. METHODS: Circulating PTX3 levels were measured in 93 PMR patients at disease onset and during corticosteroid therapy and in 46 normal controls (NC) by ELISA. RESULTS: No difference in PTX3 concentrations was observed between NC and PMR either at disease onset and during follow-up or between groups of patients defined according to the presence of recurrence/relapse. CONCLUSIONS:PTX3 serum levels do not increase significantly in active PMR. Further studies on patients with giant-cell arteritis could evaluate whether large vessel involvement may be associated to increased PTX3 levels.
Authors: Matti Vänskä; Irma Koivula; Sari Hämäläinen; Kari Pulkki; Tapio Nousiainen; Esa Jantunen; Auni Juutilainen Journal: Haematologica Date: 2011-09 Impact factor: 9.941
Authors: Giuseppe A Ramirez; Patrizia Rovere-Querini; Miriam Blasi; Silvia Sartorelli; Maria Chiara Di Chio; Mattia Baldini; Rebecca De Lorenzo; Enrica P Bozzolo; Roberto Leone; Alberto Mantovani; Angelo A Manfredi; Enrico Tombetti Journal: Front Immunol Date: 2019-05-29 Impact factor: 7.561
Authors: Raija Uusitalo-Seppälä; Reetta Huttunen; Janne Aittoniemi; Pertti Koskinen; Aila Leino; Tero Vahlberg; Esa M Rintala Journal: PLoS One Date: 2013-01-14 Impact factor: 3.240